|
MX2007004781A
(es)
*
|
2004-10-20 |
2007-05-11 |
Applied Research Systems |
Derivados de 3-arilamino piridina.
|
|
DE602006021205D1
(de)
*
|
2005-10-07 |
2011-05-19 |
Exelixis Inc |
Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
|
|
GB0601962D0
(en)
|
2006-01-31 |
2006-03-15 |
Ucb Sa |
Therapeutic agents
|
|
JP2010500994A
(ja)
*
|
2006-08-16 |
2010-01-14 |
エグゼリクシス， インコーポレイテッド |
Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法
|
|
WO2008055236A2
(en)
|
2006-10-31 |
2008-05-08 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors
|
|
JP5311673B2
(ja)
*
|
2006-12-14 |
2013-10-09 |
エグゼリクシス， インコーポレイテッド |
Ｍｅｋ阻害剤の使用方法
|
|
WO2008124085A2
(en)
*
|
2007-04-03 |
2008-10-16 |
Exelixis, Inc. |
Methods of using combinations of mek and jak-2 inhibitors
|
|
EP2155666A1
(en)
*
|
2007-05-10 |
2010-02-24 |
Pfizer Limited |
Azetidine derivatives and their use as prostaglandin e2 antagonists
|
|
NZ583367A
(en)
|
2007-07-16 |
2012-10-26 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
CL2008002083A1
(es)
|
2007-07-16 |
2008-11-21 |
Genentech Inc |
Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico
|
|
GB0714384D0
(en)
|
2007-07-23 |
2007-09-05 |
Ucb Pharma Sa |
theraputic agents
|
|
EP2240494B1
(en)
|
2008-01-21 |
2016-03-30 |
UCB Biopharma SPRL |
Thieno-pyridine derivatives as mek inhibitors
|
|
ES2643239T3
(es)
|
2008-01-31 |
2017-11-21 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
|
HUE035184T2
(en)
|
2008-03-18 |
2018-05-02 |
Genentech Inc |
Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
|
|
GB0811304D0
(en)
|
2008-06-19 |
2008-07-30 |
Ucb Pharma Sa |
Therapeutic agents
|
|
EP2307364B1
(en)
|
2008-07-01 |
2013-06-19 |
Genentech, Inc. |
Isoindolone derivatives as mek kinase inhibitors and methods of use
|
|
EP2310373A1
(en)
|
2008-07-01 |
2011-04-20 |
Genentech, Inc. |
Bicyclic heterocycles as mek kinase inhibitors
|
|
US9084781B2
(en)
|
2008-12-10 |
2015-07-21 |
Novartis Ag |
MEK mutations conferring resistance to MEK inhibitors
|
|
BRPI1006189A2
(pt)
|
2009-03-12 |
2020-08-18 |
Genentech Inc |
uso de uma combinação terapêutica, formulação farmacêutica, artigo de manufatura, produto, método para determinar compostos a serem utilizados em combinação para o tratamento de uma malignidade hematopoiética e método para selecionar compostos a serem utilizados em combinação para o tratamento de câncer
|
|
US8173650B2
(en)
|
2009-05-27 |
2012-05-08 |
Genentech, Inc. |
Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
|
|
JP5546636B2
(ja)
|
2009-09-28 |
2014-07-09 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ベンゾキセピンｐｉ３ｋ阻害剤化合物及び使用方法
|
|
RU2654068C1
(ru)
|
2009-09-28 |
2018-05-16 |
Ф.Хоффманн-Ля Рош Аг |
Бензоксазепиновые ингибиторы pi3 и способы применения
|
|
US20110086837A1
(en)
*
|
2009-10-12 |
2011-04-14 |
Genentech, Inc. |
Combinations of a pi3k inhibitor and a mek inhibitor
|
|
EA201200651A1
(ru)
*
|
2009-11-04 |
2012-12-28 |
Новартис Аг |
Гетероциклические сульфонамидные производные, применимые в качестве ингибиторов мек
|
|
WO2011069074A2
(en)
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
|
|
EP2526102B1
(en)
|
2010-01-22 |
2017-03-08 |
Fundación Centro Nacional de Investigaciones Oncológicas Carlos III |
Inhibitors of PI3 kinase
|
|
EP2539337A1
(en)
|
2010-02-22 |
2013-01-02 |
F. Hoffmann-La Roche AG |
Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
|
|
MX340392B
(es)
|
2010-02-25 |
2016-07-06 |
Dana Farber Cancer Inst Inc |
Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
|
|
CN103038364A
(zh)
|
2010-03-09 |
2013-04-10 |
达纳－法伯癌症研究所公司 |
诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
|
|
WO2011121317A1
(en)
|
2010-04-01 |
2011-10-06 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
|
|
SG184475A1
(en)
|
2010-04-07 |
2012-11-29 |
Hoffmann La Roche |
Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
|
|
WO2011130598A1
(en)
|
2010-04-15 |
2011-10-20 |
Spirogen Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
CN110818724B
(zh)
|
2010-05-07 |
2020-11-13 |
吉利德康涅狄格有限公司 |
吡啶酮和氮杂吡啶酮化合物及使用方法
|
|
CA2802808A1
(en)
|
2010-07-14 |
2012-01-19 |
F. Hoffmann-La Roche Ag |
Purine compounds selective for pi3k p110 delta, and methods of use
|
|
EP2598661B1
(en)
|
2010-07-26 |
2017-09-27 |
Biomatrica, INC. |
Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
|
|
WO2012018638A2
(en)
|
2010-07-26 |
2012-02-09 |
Biomatrica, Inc. |
Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
|
|
JP5842004B2
(ja)
|
2010-09-01 |
2016-01-13 |
ジーアイリード コネチカット インコーポレーテッドＧｉｌｅａｄ Ｃｏｎｎｅｃｔｉｃｕｔ，Ｉｎｃ． |
ピリダジノン、その製造方法及びその使用方法
|
|
US9249123B2
(en)
|
2010-09-01 |
2016-02-02 |
Genentech, Inc. |
Pyridinones/pyrazinones, method of making, and method of use thereof
|
|
WO2012052745A1
(en)
|
2010-10-21 |
2012-04-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
Combinations of pi3k inhibitors with a second anti -tumor agent
|
|
US20140080810A1
(en)
|
2010-11-15 |
2014-03-20 |
Exelixis, Inc. |
Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
|
|
CA2820078C
(en)
|
2010-12-16 |
2019-02-12 |
F. Hoffmann-La Roche Ag |
Tricyclic pi3k inhibitor compounds and methods of use
|
|
JP5766820B2
(ja)
|
2011-02-09 |
2015-08-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｐｉ３キナーゼ阻害剤としての複素環化合物
|
|
MX340013B
(es)
|
2011-03-21 |
2016-06-22 |
Hoffmann La Roche |
Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso.
|
|
CN102718750B
(zh)
*
|
2011-03-31 |
2015-03-11 |
中国人民解放军军事医学科学院毒物药物研究所 |
含吖啶环的氨基吡啶类衍生物及其用途
|
|
CN103841975A
(zh)
|
2011-04-01 |
2014-06-04 |
基因泰克公司 |
Akt抑制剂化合物和厄洛替尼的组合以及使用方法
|
|
CN103841976A
(zh)
*
|
2011-04-01 |
2014-06-04 |
基因泰克公司 |
Akt和mek抑制剂化合物的组合及其使用方法
|
|
KR101953210B1
(ko)
|
2011-05-19 |
2019-02-28 |
푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ |
단백질 키나아제 억제제로서의 대환식 화합물
|
|
EP2524918A1
(en)
|
2011-05-19 |
2012-11-21 |
Centro Nacional de Investigaciones Oncológicas (CNIO) |
Imidazopyrazines derivates as kinase inhibitors
|
|
AR086647A1
(es)
|
2011-06-03 |
2014-01-15 |
Hoffmann La Roche |
Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k
|
|
EA026924B1
(ru)
|
2011-08-01 |
2017-05-31 |
Дженентек, Инк. |
Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
|
|
BR112014003296A2
(pt)
|
2011-08-12 |
2017-03-14 |
Hoffmann La Roche |
composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença ou distúrbio, conjunto para o tratamento de uma condição mediada pela quinase pim e utilização do composto
|
|
US8614206B2
(en)
|
2011-09-27 |
2013-12-24 |
F. Hoffmann-La Roche Ag |
Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
|
|
WO2013055987A1
(en)
|
2011-10-14 |
2013-04-18 |
Spirogen Sàrl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
CA2850034A1
(en)
*
|
2011-10-28 |
2013-05-02 |
Genentech, Inc. |
Therapeutic combinations and methods of treating melanoma
|
|
RU2622391C2
(ru)
|
2011-11-03 |
2017-06-15 |
Ф. Хоффманн-Ля Рош Аг |
Соединения 8-фторфталазин-1(2н)-она в качестве ингибиторов тирозинкиназы брутона
|
|
KR20140096100A
(ko)
|
2011-11-03 |
2014-08-04 |
에프. 호프만-라 로슈 아게 |
이환 피페라진 화합물
|
|
BR112014010439A2
(pt)
|
2011-11-03 |
2017-04-18 |
F Hoffmann - La Roche Ag |
compostos, composição farmacêutica, processo de produção, método de tratamento de uma doença ou distúrbio, métodos, kit e uso de uma composição farmacêutica
|
|
UA111756C2
(uk)
|
2011-11-03 |
2016-06-10 |
Ф. Хоффманн-Ля Рош Аг |
Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
|
|
EP2592103A1
(en)
|
2011-11-08 |
2013-05-15 |
Adriacell S.p.A. |
Polymer aldehyde derivatives
|
|
CN104302669A
(zh)
|
2011-11-23 |
2015-01-21 |
伊格尼卡生物治疗公司 |
抗cd98抗体及其使用方法
|
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
|
CN103204827B
(zh)
|
2012-01-17 |
2014-12-03 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
|
|
US9897607B2
(en)
|
2012-02-01 |
2018-02-20 |
The Governors Of The University Of Alberta |
Methods, kits, and systems for treatment of metastatic papillary thyroid cancer
|
|
US20150141470A1
(en)
|
2012-05-08 |
2015-05-21 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
KR101915942B1
(ko)
|
2012-06-08 |
2018-11-06 |
에프. 호프만-라 로슈 아게 |
암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
|
|
EP2867232B1
(en)
|
2012-06-27 |
2018-08-08 |
F.Hoffmann-La Roche Ag |
5-azaindazole compounds and methods of use
|
|
MX2015001407A
(es)
|
2012-08-02 |
2015-05-08 |
Genentech Inc |
Inmunoconjugados y anticuerpos anti-etbr.
|
|
BR112015002193A2
(pt)
|
2012-08-02 |
2017-07-04 |
Genentech Inc |
anticorpos anti-etbr e imunoconjugados
|
|
CA2882292C
(en)
*
|
2012-08-13 |
2023-10-17 |
The Rockefeller University |
Treatment and diagnosis of melanoma
|
|
SI2884979T1
(sl)
|
2012-08-17 |
2019-10-30 |
Hoffmann La Roche |
Kombinirana zdravljenja melanoma, ki vključujejo dajanje kobimetiniba in vemurafeniba
|
|
CN104583215B
(zh)
|
2012-08-30 |
2016-12-07 |
霍夫曼-拉罗奇有限公司 |
二噁烯并-和噁嗪-[2,3-d]嘧啶pi3k抑制剂化合物及使用方法
|
|
JP6666147B2
(ja)
|
2012-09-26 |
2020-03-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
環状エーテルピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物と使用方法
|
|
CA2887129A1
(en)
|
2012-10-09 |
2014-04-17 |
Igenica, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
|
KR101645905B1
(ko)
|
2012-10-12 |
2016-08-04 |
스피로즌 살 |
피롤로벤조디아제핀 및 그의 컨주게이트
|
|
WO2014057117A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
|
HRP20181646T2
(hr)
|
2012-10-12 |
2019-08-09 |
Adc Therapeutics Sa |
Konjugati pirolobenzodiazepin - anti-psma protutijela
|
|
WO2014057120A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
|
ES2680153T3
(es)
|
2012-10-12 |
2018-09-04 |
Adc Therapeutics Sa |
Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
|
|
JP6300042B2
(ja)
*
|
2012-10-12 |
2018-03-28 |
エグゼリクシス， インコーポレイテッド |
癌の処置に使用するための化合物の製造方法
|
|
PL2906251T3
(pl)
|
2012-10-12 |
2018-02-28 |
Adc Therapeutics Sa |
Koniugaty pirolobenzodiazepina-przeciwciało anty-CD22
|
|
HRP20190366T1
(hr)
|
2012-10-12 |
2019-04-19 |
Medimmune Limited |
Pirolobenzodiazepini i njihovi konjugati
|
|
MX364328B
(es)
|
2012-10-12 |
2019-04-23 |
Medimmune Ltd |
Conjugados del anticuerpo pirrolobenzodiazepina.
|
|
WO2014074785A1
(en)
|
2012-11-08 |
2014-05-15 |
Ludwig Institute For Cancer Research Ltd. |
Methods of predicting outcome and treating breast cancer
|
|
CA2889381C
(en)
*
|
2012-11-15 |
2023-01-03 |
Duquesne University Of The Holy Ghost |
Carboxylic acid ester prodrug inhibitors of mek
|
|
TW201441193A
(zh)
*
|
2012-12-06 |
2014-11-01 |
Kyowa Hakko Kirin Co Ltd |
吡啶酮化合物
|
|
EP2934572A4
(en)
|
2012-12-20 |
2016-11-23 |
Biomatrica Inc |
FORMULATIONS AND METHODS FOR STABILIZING PCR REAGENTS
|
|
CN105246894A
(zh)
|
2012-12-21 |
2016-01-13 |
斯皮罗根有限公司 |
用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
|
|
AU2013366493B2
(en)
|
2012-12-21 |
2017-08-24 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
RU2019109456A
(ru)
|
2013-02-22 |
2019-04-10 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Новые конъюгаты антител и их применения
|
|
EP2958592A1
(en)
|
2013-02-22 |
2015-12-30 |
F. Hoffmann-La Roche AG |
Methods of treating cancer and preventing drug resistance
|
|
US10139415B2
(en)
|
2013-02-27 |
2018-11-27 |
Daiichi Sankyo Company, Limited |
Method for predicting responsiveness to compound inhibiting MAPK signal transduction pathway
|
|
EP2968585B1
(en)
|
2013-03-13 |
2018-07-18 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
JP6445519B2
(ja)
|
2013-03-13 |
2018-12-26 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
|
WO2014140862A2
(en)
|
2013-03-13 |
2014-09-18 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
BR112015022576A2
(pt)
|
2013-03-14 |
2017-10-24 |
Genentech Inc |
produto farmacêutico e seu uso, kit e método para tratar uma disfunção hiperproliferativa
|
|
IL283717B
(en)
|
2013-03-15 |
2022-09-01 |
Cancer Research Tech Llc |
Methods and compositions for gamma-glutamyl cycle modulation
|
|
WO2014153495A2
(en)
|
2013-03-22 |
2014-09-25 |
University Of Hawaii |
Novel stat3 inhibitors
|
|
JP6824735B2
(ja)
|
2013-06-06 |
2021-02-03 |
ピエール、ファーブル、メディカマン |
抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
|
|
EP3007556B1
(en)
|
2013-06-13 |
2020-05-20 |
Biomatrica, INC. |
Cell stabilization
|
|
WO2015000949A1
(en)
|
2013-07-03 |
2015-01-08 |
F. Hoffmann-La Roche Ag |
Heteroaryl pyridone and aza-pyridone amide compounds
|
|
WO2015031698A1
(en)
|
2013-08-28 |
2015-03-05 |
Stem Centrx, Inc. |
Site-specific antibody conjugation methods and compositions
|
|
US9532987B2
(en)
|
2013-09-05 |
2017-01-03 |
Genentech, Inc. |
Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
|
|
SG11201510740YA
(en)
|
2013-09-17 |
2016-01-28 |
Obi Pharma Inc |
Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
|
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
EP3054986B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
US10010624B2
(en)
|
2013-10-11 |
2018-07-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
US9950078B2
(en)
|
2013-10-11 |
2018-04-24 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EP3077384B1
(en)
|
2013-12-05 |
2017-09-06 |
F. Hoffmann-La Roche AG |
Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
|
|
WO2015108203A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社オーダーメードメディカルリサーチ |
抗ｓｌｃ６ａ６抗体を用いたがん治療用医薬組成物
|
|
CN104788365B
(zh)
*
|
2014-01-16 |
2018-08-10 |
上海艾力斯医药科技有限公司 |
异烟酰胺衍生物、其制备方法及应用
|
|
KR20160127140A
(ko)
|
2014-03-18 |
2016-11-02 |
에프. 호프만-라 로슈 아게 |
옥세판-2-일-피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
|
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
|
US10266603B2
(en)
|
2014-04-18 |
2019-04-23 |
The Governors Of The University Of Alberta |
Targeted therapy to restore radioactive iodine transport in thyroid cancer
|
|
RU2020120593A
(ru)
|
2014-04-25 |
2020-09-01 |
Дженентек, Инк. |
Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
|
|
WO2015172073A1
(en)
|
2014-05-08 |
2015-11-12 |
Cornell University |
Bio-adhesive gels and methods of use
|
|
WO2015182734A1
(ja)
*
|
2014-05-30 |
2015-12-03 |
協和発酵キリン株式会社 |
含窒素複素環化合物
|
|
JP6661554B2
(ja)
|
2014-06-10 |
2020-03-11 |
バイオマトリカ，インク． |
周囲温度における血小板の安定化
|
|
EP3563870A1
(en)
|
2014-07-15 |
2019-11-06 |
F. Hoffmann-La Roche AG |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
WO2016037644A1
(en)
|
2014-09-10 |
2016-03-17 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
AU2015314954B2
(en)
|
2014-09-12 |
2021-05-13 |
Genentech, Inc. |
Anti-HER2 antibodies and immunoconjugates
|
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
US10077318B2
(en)
|
2014-09-12 |
2018-09-18 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
|
WO2016044396A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
|
|
JP2017533887A
(ja)
|
2014-09-17 |
2017-11-16 |
ジェネンテック， インコーポレイテッド |
ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
|
|
CN106922146B
(zh)
|
2014-10-02 |
2020-05-26 |
豪夫迈·罗氏有限公司 |
用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
|
|
US20170224670A1
(en)
|
2014-10-14 |
2017-08-10 |
Exelixis, Inc. |
Drug Combination to Treat Melanoma
|
|
US10780096B2
(en)
|
2014-11-25 |
2020-09-22 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
CA2970352A1
(en)
|
2014-12-11 |
2016-06-16 |
Pierre Fabre Medicament |
Anti-c10orf54 antibodies and uses thereof
|
|
WO2016095088A1
(en)
*
|
2014-12-15 |
2016-06-23 |
Merck Sharp & Dohme Corp. |
Erk inhibitors
|
|
WO2016095089A1
(en)
|
2014-12-15 |
2016-06-23 |
Merck Sharp & Dohme Corp. |
Erk inhibitors
|
|
CN112375078B
(zh)
|
2014-12-18 |
2023-12-19 |
豪夫迈·罗氏有限公司 |
四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
|
|
JP6957035B2
(ja)
|
2015-04-10 |
2021-11-02 |
トーマス・ジェファーソン・ユニバーシティ |
対象への移植用の免疫原性拡散チャンバおよびその調製方法
|
|
GB201506389D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
WO2016196373A2
(en)
|
2015-05-30 |
2016-12-08 |
Genentech, Inc. |
Methods of treating her2-positive metastatic breast cancer
|
|
EP3307780A1
(en)
|
2015-06-15 |
2018-04-18 |
Genentech, Inc. |
Antibodies and immunoconjugates
|
|
AR105483A1
(es)
*
|
2015-06-30 |
2017-10-11 |
Exelixis Inc |
Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
|
|
EP3881833B1
(en)
|
2015-06-30 |
2023-11-01 |
Genentech, Inc. |
Immediate-release tablets containing a drug and processes for forming the tablets
|
|
EP4585597A1
(en)
|
2015-07-02 |
2025-07-16 |
F. Hoffmann-La Roche AG |
Benzoxazepin oxazolidinone compounds and methods of use
|
|
CN107995911B
(zh)
|
2015-07-02 |
2020-08-04 |
豪夫迈·罗氏有限公司 |
苯并氧氮杂*噁唑烷酮化合物及其使用方法
|
|
WO2017033113A1
(en)
|
2015-08-21 |
2017-03-02 |
Acerta Pharma B.V. |
Therapeutic combinations of a mek inhibitor and a btk inhibitor
|
|
JP2018532990A
(ja)
|
2015-09-04 |
2018-11-08 |
オービーアイ ファーマ，インコーポレイテッド |
グリカンアレイおよび使用の方法
|
|
BR112018008882A8
(pt)
|
2015-11-03 |
2019-02-26 |
Univ Texas |
método para tratar um distúrbio proliferativo e produto farmacêutico
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
CN121154828A
(zh)
|
2015-11-19 |
2025-12-19 |
豪夫迈·罗氏有限公司 |
使用b-raf抑制剂和免疫检查点抑制剂治疗癌症的方法
|
|
JP6827048B2
(ja)
|
2015-12-08 |
2021-02-10 |
バイオマトリカ，インク． |
赤血球沈降速度の低下
|
|
CN105330643B
(zh)
*
|
2015-12-09 |
2017-12-05 |
苏州明锐医药科技有限公司 |
卡比替尼的制备方法
|
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
BR112018069530B1
(pt)
|
2016-02-29 |
2021-02-17 |
F. Hoffmann-La Roche Ag |
composições de forma de dosagem que compreendem um inibidor da tirosina quinase de bruton
|
|
US11883404B2
(en)
|
2016-03-04 |
2024-01-30 |
Taiho Pharmaceuticals Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
|
KR20220110859A
(ko)
|
2016-03-04 |
2022-08-09 |
다이호야쿠힌고교 가부시키가이샤 |
악성 종양 치료용 제제 및 조성물
|
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
|
TWI780045B
(zh)
|
2016-03-29 |
2022-10-11 |
台灣浩鼎生技股份有限公司 |
抗體、醫藥組合物及方法
|
|
CN109072311A
(zh)
|
2016-04-15 |
2018-12-21 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
|
AU2017252128B2
(en)
|
2016-04-22 |
2024-06-06 |
Obi Pharma, Inc. |
Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
|
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
CN106045969B
(zh)
*
|
2016-05-27 |
2019-04-12 |
湖南欧亚药业有限公司 |
一种卡比替尼的合成方法
|
|
WO2017216280A1
(en)
|
2016-06-16 |
2017-12-21 |
F. Hoffmann-La Roche Ag |
TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
|
|
CN109311876B
(zh)
|
2016-06-16 |
2022-05-03 |
豪夫迈·罗氏有限公司 |
杂芳基雌激素受体调节剂及其用途
|
|
CN106220607B
(zh)
*
|
2016-07-27 |
2018-09-18 |
成都百事兴科技实业有限公司 |
一种s-3-(哌啶-2-基)-氮杂环丁烷-3-醇的合成方法
|
|
KR20230117482A
(ko)
|
2016-07-27 |
2023-08-08 |
오비아이 파머 인코퍼레이티드 |
면역원성/치료 글리칸 조성물 및 그의 용도
|
|
JP7121724B2
(ja)
|
2016-07-29 |
2022-08-18 |
オービーアイ ファーマ，インコーポレイテッド |
ヒト抗体、医薬組成物及び方法
|
|
BR112019002036A2
(pt)
|
2016-08-12 |
2019-05-14 |
Genentech Inc |
métodos de tratamento de um sujeito com câncer colorretal, kit para tratamento do câncer colorretal em um sujeito humano e combinação de fármacos para a terapia do câncer colorretal
|
|
CN109862917A
(zh)
|
2016-09-29 |
2019-06-07 |
基因泰克公司 |
Mek抑制剂,pd-1轴抑制剂,和紫杉烷的组合疗法
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
WO2018094414A1
(en)
|
2016-11-21 |
2018-05-24 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
SMT202200068T1
(it)
|
2017-02-08 |
2022-05-12 |
Adc Therapeutics Sa |
Coniugati di pirrolobenzodiazepina-anticorpo
|
|
UA125198C2
(uk)
|
2017-02-08 |
2022-01-26 |
Ейдісі Терапьютікс Са |
Кон'югати піролобензодіазепін-антитіло
|
|
CN106866624B
(zh)
*
|
2017-02-27 |
2017-12-26 |
济宁医学院 |
一种卡比替尼的化学合成方法
|
|
WO2018187478A1
(en)
|
2017-04-04 |
2018-10-11 |
University Of Miami |
Biomarkers indicative of prostate cancer and treatment thereof
|
|
SI3612537T1
(sl)
|
2017-04-18 |
2022-10-28 |
Medimmune Limited |
Konjugati pirolobenzodiazepina
|
|
WO2018193102A1
(en)
|
2017-04-20 |
2018-10-25 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
|
WO2018193104A1
(en)
|
2017-04-20 |
2018-10-25 |
Adc Therapeutics Sa |
Combination therapy with an anti-cd25 antibody-drug conjugate
|
|
WO2018229218A1
(en)
|
2017-06-14 |
2018-12-20 |
Adc Therapeutics Sa |
Dosage regimes for the administration of an anti-cd25 adc
|
|
JP7145891B2
(ja)
|
2017-06-14 |
2022-10-03 |
アーデーセー セラピューティクス ソシエテ アノニム |
抗ｃｄ１９ ａｄｃを投与するための投与レジメ
|
|
BR112020003003A2
(pt)
|
2017-08-18 |
2020-08-11 |
Medimmune Limited |
conjugados de pirrolobenzodiazepina
|
|
KR102811888B1
(ko)
|
2017-09-08 |
2025-05-27 |
에프. 호프만-라 로슈 아게 |
암의 진단 및 치료 방법
|
|
EP3752200A1
(en)
|
2018-02-13 |
2020-12-23 |
Vib Vzw |
Targeting minimal residual disease in cancer with rxr antagonists
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
MX2020009762A
(es)
|
2018-03-19 |
2021-01-08 |
Taiho Pharmaceutical Co Ltd |
Composicion farmaceutica que incluye alquil sulfato de sodio.
|
|
US12280039B2
(en)
|
2018-03-21 |
2025-04-22 |
Colorado State University Research Foundation |
Cancer vaccine compositions and methods of use thereof
|
|
JPWO2019188595A1
(ja)
|
2018-03-26 |
2020-12-03 |
富士フイルム株式会社 |
感光性樹脂組成物及びその製造方法、レジスト膜、パターン形成方法、並びに、電子デバイスの製造方法
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
JP2021524449A
(ja)
|
2018-05-23 |
2021-09-13 |
アーデーセー セラピューティクス ソシエテ アノニム |
分子アジュバント
|
|
TWI853822B
(zh)
|
2018-06-27 |
2024-09-01 |
台灣浩鼎生技股份有限公司 |
用於糖蛋白工程的糖苷合成酶變體及其使用方法
|
|
GB201811364D0
(en)
|
2018-07-11 |
2018-08-29 |
Adc Therapeutics Sa |
Combination therapy
|
|
MA53160A
(fr)
|
2018-07-20 |
2021-05-26 |
Pf Medicament |
Récepteur pour vista
|
|
JP7590083B2
(ja)
|
2018-08-31 |
2024-11-26 |
アーデーセー セラピューティクス ソシエテ アノニム |
併用療法
|
|
WO2020079581A1
(en)
|
2018-10-16 |
2020-04-23 |
Novartis Ag |
Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
|
|
JP7546297B2
(ja)
*
|
2018-11-20 |
2024-09-06 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚障害の処置のためのチエニル－アニリン化合物
|
|
CA3120351A1
(en)
*
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
|
|
CA3120337A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Naphthyridinone-aniline compounds for treatment of dermal disorders
|
|
MA55141A
(fr)
|
2018-11-20 |
2021-09-29 |
Nflection Therapeutics Inc |
Composés cyanoaryl-aniline pour le traitement d'affections de la peau
|
|
WO2020109251A1
(en)
|
2018-11-29 |
2020-06-04 |
Adc Therapeutics Sa |
Dosage regime
|
|
WO2020127573A1
(en)
|
2018-12-19 |
2020-06-25 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine resistance
|
|
GB201820725D0
(en)
|
2018-12-19 |
2019-01-30 |
Adc Therapeutics Sarl |
Pyrrolobenzodiazepine resistance
|
|
US20220040324A1
(en)
|
2018-12-21 |
2022-02-10 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
|
WO2020187674A1
(en)
|
2019-03-15 |
2020-09-24 |
Sandoz Ag |
Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
|
|
MX2021010477A
(es)
|
2019-03-15 |
2021-10-01 |
Medimmune Ltd |
Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
|
|
BR112021018168B1
(pt)
|
2019-03-21 |
2023-11-28 |
Onxeo |
Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
|
|
CN118221763A
(zh)
|
2019-03-29 |
2024-06-21 |
免疫医疗有限公司 |
化合物及其缀合物
|
|
TWI735210B
(zh)
|
2019-04-26 |
2021-08-01 |
中國醫藥大學 |
Ａｄａｍ９抑制劑作為免疫調節劑之用途
|
|
GB201908128D0
(en)
|
2019-06-07 |
2019-07-24 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
CN114302745A
(zh)
|
2019-06-10 |
2022-04-08 |
Adc治疗有限公司 |
包含抗cd19抗体药物缀合物以及pi3k抑制剂或第二剂的组合疗法
|
|
JP2022536140A
(ja)
|
2019-06-10 |
2022-08-12 |
アーデーセー セラピューティクス ソシエテ アノニム |
併用療法
|
|
GEP20247627B
(en)
|
2019-07-22 |
2024-05-27 |
Lupin Ltd |
Macrocyclic compounds as sting agonists and methods and uses thereof
|
|
GB201912059D0
(en)
|
2019-08-22 |
2019-10-09 |
Bergenbio As |
Combaination therapy of a patient subgroup
|
|
US20240123081A1
(en)
|
2019-10-25 |
2024-04-18 |
Medimmune, Llc |
Branched moiety for use in conjugates
|
|
CA3159348A1
(en)
|
2019-11-08 |
2021-05-14 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
|
|
GB201917254D0
(en)
|
2019-11-27 |
2020-01-08 |
Adc Therapeutics Sa |
Combination therapy
|
|
JP7689964B2
(ja)
|
2019-12-13 |
2025-06-09 |
インスピルナ，インコーポレーテッド |
金属塩及びその使用
|
|
CN111170990B
(zh)
*
|
2020-01-16 |
2021-01-05 |
广州科锐特生物科技有限公司 |
一种3-哌啶-2-基-氮杂环丁烷-3-醇衍生物的制备方法
|
|
KR20220130749A
(ko)
|
2020-01-22 |
2022-09-27 |
메디뮨 리미티드 |
화합물 및 이의 접합체
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
TW202140076A
(zh)
|
2020-01-22 |
2021-11-01 |
英商梅迪繆思有限公司 |
化合物及其軛合物
|
|
GB202004189D0
(en)
|
2020-03-23 |
2020-05-06 |
Bergenbio As |
Combination therapy
|
|
WO2021206167A1
(ja)
|
2020-04-10 |
2021-10-14 |
大鵬薬品工業株式会社 |
３，５－二置換ベンゼンアルキニル化合物とｍｅｋ阻害剤とを用いた癌治療法
|
|
US11701427B2
(en)
|
2020-04-16 |
2023-07-18 |
Regeneron Pharmaceuticals, Inc. |
Diels-alder conjugation methods
|
|
GB202006072D0
(en)
|
2020-04-24 |
2020-06-10 |
Bergenbio Asa |
Method of selecting patients for treatment with cmbination therapy
|
|
EP3915576A1
(en)
|
2020-05-28 |
2021-12-01 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Chimeric antigen receptors specific for p95her2 and uses thereof
|
|
EP3939999A1
(en)
|
2020-07-14 |
2022-01-19 |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
|
|
GB202011993D0
(en)
|
2020-07-31 |
2020-09-16 |
Adc Therapeutics Sa |
ANTI-IL 13Ra2 antibodies
|
|
GB202012161D0
(en)
|
2020-08-05 |
2020-09-16 |
Adc Therapeutics Sa |
Combination therapy
|
|
MX2023001865A
(es)
|
2020-08-14 |
2023-05-09 |
Guangzhou Lupeng Pharmaceutical Company Ltd |
Composiciones de forma de dosificación que comprenden un inhibidor de btk y mutantes de este.
|
|
GB202015226D0
(en)
|
2020-09-25 |
2020-11-11 |
Adc Therapeutics S A |
Pyrrol obenzodiazepine-antibody conugates and uses thereof
|
|
GB202015916D0
(en)
|
2020-10-07 |
2020-11-18 |
Adc Therapeutics Sa |
Combination therapy
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
US20240173329A1
(en)
|
2021-03-09 |
2024-05-30 |
Genentech, Inc. |
Belvarafenib for use in treatment of brain cancers
|
|
EP4308935A1
(en)
|
2021-03-18 |
2024-01-24 |
Novartis AG |
Biomarkers for cancer and methods of use thereof
|
|
US20240366609A1
(en)
|
2021-04-06 |
2024-11-07 |
Genentech, Inc. |
Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab
|
|
US12280055B2
(en)
|
2021-05-27 |
2025-04-22 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
GB202107709D0
(en)
|
2021-05-28 |
2021-07-14 |
Adc Therapeutics S A |
Combination therapy
|
|
GB202107713D0
(en)
|
2021-05-28 |
2021-07-14 |
Medimmune Ltd |
Combination therapy
|
|
GB202107706D0
(en)
|
2021-05-28 |
2021-07-14 |
Adc Therapeutics S A |
Combination therapy
|
|
KR102699226B1
(ko)
|
2021-06-09 |
2024-08-27 |
에프. 호프만-라 로슈 아게 |
암 치료를 위한 병용요법
|
|
MX2023015264A
(es)
|
2021-06-29 |
2024-01-19 |
Adc Therapeutics Sa |
Terapia de combinaicon con conjugados de anticuerpo-farmaco.
|
|
WO2023057545A1
(en)
|
2021-10-06 |
2023-04-13 |
Microquin Ltd. |
Substituted chalcones
|
|
WO2023078881A1
(en)
|
2021-11-04 |
2023-05-11 |
F. Hoffmann-La Roche Ag |
Novel use of quinazolinone compound for the treatment of cancer
|
|
EP4436570A4
(en)
|
2021-11-23 |
2025-10-22 |
Nflection Therapeutics Inc |
FORMULATIONS OF PYRROLOPYRIDINE-ANILINE COMPOUNDS
|
|
JP2025503456A
(ja)
|
2021-12-16 |
2025-02-04 |
アールディーピー ファーマ アーゲー |
細胞膜透過性ポリペプチド（ｃｐｐ）及びヒト治療におけるそれらの使用
|
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|
|
EP4493169A4
(en)
*
|
2022-03-17 |
2026-03-04 |
Springworks Therapeutics Inc |
Fluorinated phenylamine compounds and pharmaceutical compositions
|
|
EP4253418A1
(en)
|
2022-03-29 |
2023-10-04 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
|
|
GB202209285D0
(en)
|
2022-06-24 |
2022-08-10 |
Bergenbio Asa |
Dosage regimen for AXL inhibitor
|
|
WO2024033381A1
(en)
|
2022-08-10 |
2024-02-15 |
Vib Vzw |
Inhibition of tcf4/itf2 in the treatment of cancer
|
|
CN120265291A
(zh)
|
2022-11-18 |
2025-07-04 |
豪夫迈·罗氏有限公司 |
喹唑啉酮化合物的新用途和制剂
|
|
EP4406973A1
(en)
|
2023-01-27 |
2024-07-31 |
Fundació Privada Institut de Recerca de la SIDA-Caixa |
Antibodies and uses thereof for the treatment of infections caused by enveloped viruses
|
|
AU2023439518A1
(en)
|
2023-04-06 |
2025-08-28 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumors
|
|
WO2024229406A1
(en)
|
2023-05-04 |
2024-11-07 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
WO2025029650A1
(en)
|
2023-07-28 |
2025-02-06 |
Li Xiyan |
Nutritionally modified diets comprising aminoacids for use in treating a disease
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
TW202530228A
(zh)
|
2023-10-12 |
2025-08-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026019990A1
(en)
|
2024-07-18 |
2026-01-22 |
Genentech, Inc. |
Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies
|
|
WO2026024841A1
(en)
|
2024-07-24 |
2026-01-29 |
Astellas Us Llc |
Bispecific antibodies that bind cd3 and muc1 and methods of use thereof
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|